Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.

The acquisition brings closure for Mirati at last, though some investors will feel disappointed.

Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.

But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.

But Repare and Black Diamond still have rebuilding to do.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.